¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Bone Density Conservation Agents"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • bone
    »À, °ñ
  • bone age
    »À³ªÀÌ, °ñ¿¬·É
  • bone canaliculus
    »À¼¼°ü, °ñ¼Ò°ü
  • bone chip
    »ÄÁ¶°¢, °ñÆÄÆí
  • bone chisel
    »À²ø
  • bone clamp
    »ÀŬ·¥ÇÁ, »À¹°°³
  • bone conduction
    »ÀÀüµµ, °ñÀüµµ
  • bone conduction audiometry
    »ÀÀüµµÃ»·Â°Ë»ç, °ñÀüµµÃ»·Â°Ë»ç
  • bone conduction curve
    »ÀÀüµµÃ»·Â°î¼±, °ñÀüµµÃ»·Â°î¼±
  • bone conduction hearing
    »ÀÀüµµµè±â, °ñÀüµµÃ»·Â
  • bone conduction test
    »ÀÀüµµ°Ë»ç, °ñÀüµµ°Ë»ç
  • bone deposition
    »ÀÄ§Âø, °ñÄ§Âø
  • bone dislocation
    °ñÀüÀ§, »À¾î±ß³²
  • bone drill
    »Àõ°ø±â
  • bone fragment
    »ÄÁ¶°¢, °ñÆí
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • bone marrow transplantation
    °ñ¼öÀ̽Ä(¼ú)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • bone age
    »À³ªÀÌ, °ñ¿¬·É
  • bone conduction audiometry
    »ÀÀüµµÃ»·Â°Ë»ç
  • herring bone appearance
    û¾î»À¸ð¾ç
  • herring bone artifact
    û¾î»ÀÇã»ó, û¾î»ÀÀΰø¹°
  • bone
    »À, °ñ
  • bone canaliculus
    »À¼¼°ü, °ñ¼Ò°ü
  • bone chip
    »ÀÁ¶°¢, °ñÆÄÆí, °ñ¼¼Æí
  • bone chisel
    »À²ø
  • bone clamp
    °ñ²ª¼è, »À²ª¼è
  • bone conduction
    »ÀÀüµµ
  • bone deposition
    »ÀÄ§Âø, °ñÄ§Âø
  • bone dislocation
    °ñÀüÀ§, °ñÀÌÅ», »À¾î±ß³²
  • bone drill
    »Àõ°ø±â
  • bone fragment
    »ÀÁ¶°¢, °ñÆí
  • bone fragmentation
    »ÀÁ¶°¢Çü¼º, °ñÆíÇü¼º
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • hamate bone =os hamatum
    À¯____ (êóÏÉÍé).
  • hamate bone =os hamatum
    À¯±¸ °ñ(êóÏÉÍé)£¬°¥°í¸®¡¡°ñ.
  • hammer bone =malleus
    Ãß°ñ, ¸ÁÄ¡»À{ÇØ}
  • hammer bone =malleus
    ¸ÁÄ¡»À, Ãß°ñ.
  • hamulus of hamate bone
    °¥°í¸®»À°¥°í¸®
  • haunch bone =hip b. innominate
    Á°ñ(µÐ ¿äºÎ)(¡­Ôëé¦Ý»).
  • head of metatarsal bone
    ¹ßÇ㸮»À¸Ó¸®
  • hearing, bone conduction
    °ñµµÃ»·Â
  • heel bone =calcaneus
    Á¾°ñ(ñ¢Íé).
  • heel bone =calcaneus
    Á¾°ñ(ñ¢Íé)£¬µÚ²ÞÄ¡ »À.
  • hereditary fragility of bone
    À¯Àü¼º °ñ Ãë¾àÁõ (¡­Íéöªå°ñø).
  • hereditary fragility of bone
    À¯Àü¼º °ñÃë¾àÁõ (¡­Íéöªå°ñø).
  • herring bone appearance
    û¾î»À ¸ð¾ç
  • hip bone
    °ü°ñ(ΰÍé).
  • hip bone
    º¼±â»À °ü°ñ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • energy flux density
    ¿¡³ÊÁö¼Ó¹Ðµµ
  • epitope density
    Ç׿ø°áÁ¤±â¹Ðµµ
  • equilibrium density gradient centrifugation
    ÆòÇü¹Ðµµ±¸¹è¿ø½É¹ý(¡­ÚËöôÎþÛÕêÀãýÛö).
  • familial high density lipoprotein def
    °¡Á·¼º °íºñÁ߸®Æ÷´Ü¹éÁú°áÇÌ Áõ.
  • flux density
    À¯µ¿ ¹Ðµµ
  • flux density
    ¼Ó¹Ðµµ
  • grain density
    ÀÔÀÚ<±×·¡ÀÎ>¹Ðµµ.
  • high electron density
    °íÀüÀڹеµ(ÍÔï³í­ÚËöô).
  • high-density lipoprotein
    °í¹ÐµµÁö¹æ´Ü¹é
  • incidence density
    ¹ß»ý ºóµµ
  • innervation density
    ½Å°æÁö¹è¹Ðµµ(¡­ÚËöô).
  • intermediate density lipoprotein =IDL ´ç´¢
    Áß°£ºñÁßÁö(Áú)´Ü¹é(Áú).
  • interstitial density
    °£Áú¼º À½¿µ
  • linear density
    ¼±»óÀ½¿µ
  • lipoprotein,low-density
    Àú¹Ðµµ(î¸ÚËÓø)
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Trabecula of bone
    »ÀÀܱâµÕ
    [¿¾ ¿ë¾î] °ñ¼ÒÁÖ
  • Lamella of bone
    »ÀÃþÆÇ
    [¿¾ ¿ë¾î] °ñÃþÆÇ
  • Fibrous bone marrow
    ¼¶À¯°ñ¼ö [¼¶À¯»À¼ÓÁú]
    [¿¾ ¿ë¾î] ¼¶À¯¼º°ñ¼ö
  • Reticulofibrous periosteal bone
    ¼¼¸Á¼¶À¯»À¹Ù±ù¸·»À
    [¿¾ ¿ë¾î] ¼¼¸Á¼¶À¯¼º°ñ¸·°ñ
  • Triquetral bone
    ¼¼¸ð»À
    [¿¾ ¿ë¾î] »ï°¢±Ù
  • Third metacarpal bone
    ¼Â°¼ÕÇ㸮»À
    [¿¾ ¿ë¾î] Á¦1Áß¼ö°ñ
  • Scaphoid bone
    ¼Õ¹è»À
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ
  • Tubercle of scaphoid bone
    ¼Õ¹è»À°áÀý
    [¿¾ ¿ë¾î] ÁÖ»ó°ñ°áÀý
  • Gelatinous bone marrow
    ¾Æ±³°ñ¼ö [¾Æ±³»À¼ÓÁú]
    [¿¾ ¿ë¾î] ±³¾ç°ñ¼ö
  • Gelatinous bone marrow
    ¾Æ±³°ñ¼ö [¾Æ±³»À¼ÓÁú]
    [¿¾ ¿ë¾î] ¾Æ±³°ñ¼ö
  • Medial cuneiform bone
    ¾ÈÂʽû±â»À
    [¿¾ ¿ë¾î] ³»Ãø¼³»ó°ñ
  • Capitate bone
    ¾Ë¸Ó¸®»À
    [¿¾ ¿ë¾î] À¯µÎ°ñ
  • Perichondral bone
    ¿¬°ñ¸·»À
    [¿¾ ¿ë¾î] ¿¬°ñ¸·°ñ
  • Cartilagenous bone
    ¿¬°ñ»À
    [¿¾ ¿ë¾î] ¿¬°ñ¼º°ñ
  • Definite compact bone
    ¿Ï¼ºÄ¡¹Ð»À
    [¿¾ ¿ë¾î] ¿Ï¼ºÄ¡¹Ð°ñ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • facial bone
    ¾ó±¼»À, ¾È¸é°ñ
  • flat bone
    ³³ÀÛ»À, ÆíÆò°ñ
  • frontal bone
    ÀüµÎ°ñ
  • hammer bone
    ¸ÁÄ¡»À, Ãß°ñ
  • herring bone appearance
    û¾î»À¸ð¾ç
  • hip bone
    °ü°ñ
  • iliac bone
    Àå°ñ
  • long bone
    Àå°ñ
  • malar bone
    Çù°ñ
  • marble bone
    ´ë¸®¼®°ñ
  • marble bone disease
    ´ë¸®¼®°ñº´
  • maxillary bone
    »ó¾Ç°ñ
  • membranous bone
    ¸·°ñ
  • metacarpal bone
    Áß¼ö°ñ
  • metatarsal bone
    ÁßÁ·°ñ
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
NAHPA National Association of Hospital Purchasing Agents
OHA oral hypoglycemic agents
BC Bone Conduction
BM   1) Bone Marrow
  2) Basement Membrane
  3) Bench-Mark; ¼öÁØ ±âÇ¥...
BMT Bone Marrow Transplantation;°ñ¼ö À̽Ä
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
BMD Bone mineral content and density
BMC Bone mineral density and content
TBD Trabecular bone density
v BMD volumetric bone mineral density
BPTB Bone-patellar tendon-bone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • bone blend
    °ñ È¥ÇÕ
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone chisel
    »À ²ø
  • bone conduction test
    °ñÀüµµ ½ÃÇè
  • bone curette
    °ñÅ¥·¿, °ñ ¼ÒÆÄ
  • bone cyst
    °ñ ³¶
  • bone disease
    °ñ Áúȯ
    µ¿ÀǾî=osteo
  • bone dislocation
    °ñ ÀüÀÌ, °ñ ÀüÀ§
  • bone factor
    °ñ ÀÎÀÚ
    Ȱ¼ºÀ̳ª ÀÚÁï¿¡ ´ëÇÑ Ä¡Á¶°ñÀÇ »ó´ë ¹ÝÀÀ.
  • bone file
    ¿Ü°ú¿ë ÁÙ
  • bone forcep
    °ñ °âÀÚ
  • bone fragment
    °ñÆí
  • bone graft
    °ñ À̽Ä, °ñ ÀÌ½ÄÆí
    1. »ÀÀÇ °á¼Õ º¸ÀüÀ̳ª º¸°­ µîÀ» ¸ñÀûÀ¸·Î °ñÆíÀ» À̽ÄÇÏ´Â ÀÏ. »À°¡ ¿Ü»óÀ̳ª Á¾¾ç¿¡ ÀÇÇÏ¿© ÆÄ±«µÇ¾î °á¼ÕµÈ °æ¿ìÀÇ º¸ÀüÀ̳ª, »ÀÀÇ À̴ܺΰ¡ ¾àÇÏ¿© ±Ù·Â¿¡ °ßµðÁö ¸øÇÒ ¶§ ±× ºÎºÐÀ» À̾ º¸°­Çϰųª, °ñÁúÀÌ ³ªºü °ñ À¯ÇÕÀÌ °ï¶õÇÑ °æ¿ì, »ÀÀÇ Áõ»ýÀ» ÀçÃËÇÏ¿© °ñ À¯ÇÕÀ» ÃËÁøÇÏ·Á ÇÒ ¶§¿¡ ÇàÇÑ´Ù. À̽ÄÇÏ´Â °ñÆíÀº º»ÀÎÀÇ °Í, Áï ÀÚ°¡ °ñÀÌ °¡Àå ÁÁÀ¸¸ç °ñ¹ÝÀÇ Àå°ñ, ´Á°ñ, °æ°ñ µî¿¡¼­ äÃëÇÑ´Ù. ³²ÀÇ »Àµµ ¾²À̸ç, ¶§·Î´Â ¿©·¯ °¡Áö 󸮸¦ ÇÑ µ¿¹°ÀÇ »Àµµ »ç¿ëµÈ´Ù. ÃÖ±Ù ÀϺΠ±¹°¡¿¡¼­´Â ¼ö¼ú ¶§ ÀýÁ¦ÇÑ »À³ª Àý´ÜÁöÀÇ »À, ¶Ç´Â ¿Ü»ó µîÀ¸·Î ±Þ»çÇÑ »ç¶÷ÀÇ »À¸¦ »¡¸® ¹«±ÕÀûÀ¸·Î ²¨³»¾î Àú¿Â º¸Á¸ÇÏ¿´´Ù°¡, ÇÊ¿äÇÒ ¶§ »ç¿ëÇÏ°Ô ÇÏ´Â ¡®»À ÀºÇ࡯µµ ¿î¿µµÇ°í ÀÖ´Ù. 2. °ñÀÌ °á¼ÕµÇ°Å³ª ÀýÁ¦µÈ ºÎÀ§¸¦ ¸Þ¿ì±â À§ÇÏ¿© µ¿¹° ¶Ç´Â ȯÀڷκÎÅÍ ¾òÀº ÀÌ½Ä °ñÆí.
  • bone growth
    °ñ ¼ºÀå
    »ÀÀÇ Å©±â°¡ Áõ°¡ÇÏ´Â °ÍÀ¸·Î bone maturation
  • bone hammer
    °ñ ÇØ¸Ó
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
anti-arrhythmia agents Agents used for the treatment or prevention of cardiac arrhythmias. They may affect the polarization-repolarization phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. Anti-arrhythmia agents are often classed into four main groups according to their mechanism of action: sodium channel blockade, beta-adrenergic blockade, repolarization prolongation, or calcium channel blockade.
(12 Dec 1998)
anti-asthmatic agents Drugs that are used to treat asthma.
(12 Dec 1998)
anticarcinogenic agents Agents that reduce the frequency or rate of spontaneous or induced tumours independently of the mechanism involved. They differ from antineoplastic agent in that they prevent neoplasms from forming. The anticarcinogenic substances can be divided into three categories. The first consists of compounds that prevent the formation of carcinogens from precursor substances. The second group consists of "blocking agents" which inhibit carcinogenesis by preventing carcinogenic agents from reaching or reacting with critical target sites in the tissues. The third group is the "suppressor agents" which act by suppression of expression of neoplasia in cells previously exposed to carcinogens that would otherwise cause neoplasms.
(12 Dec 1998)
anticestodal agents Agents used to treat tapeworm infestations in man or animals.
(12 Dec 1998)
anticholesteraemic agents Substances that promote a reduction of blood cholesterol levels.
(12 Dec 1998)
anti-coagulant agents Medications, like heparin, used as blood-thinners to prevent blood clots and to maintain open blood vesssels.
(12 Dec 1998)
antidepressive agents Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several monoamine oxidase inhibitors are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (antidepressive agents, tricyclic) also appear to act through brain catecholamine systems. A third group (antidepressive agents, second-generation) is a diverse group of drugs including some that act specifically on serotonergic systems.
(12 Dec 1998)
antidepressive agents, second-generation A structurally and mechanistically diverse group of drugs that are not tricyclics or monoamine oxidase inhibitors. The most clinically important appear to act selectively on serotonergic systems, especially by inhibiting serotonin reuptake.
(12 Dec 1998)
antidepressive agents, tricyclic Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.
(12 Dec 1998)
anti-dyskinesia agents Drugs used in the treatment of movement disorders. most of these act centrally on dopaminergic or cholinergic systems. Among the most important clinically are those used for the treatment of parkinson disease (antiparkinson agents) and those for the tardive dyskinesias.
(12 Dec 1998)
antifoaming agents Agents used to prevent the formation of foam or to treat flatulence or bloat.
(12 Dec 1998)
antifungal agents Agents destructive to fungi, suppressing their growth or reproduction, and effective against fungal infections. They differ from fungicides, industrial in that antifungal agents are restricted to action against fungi present in human or animal tissues.
(12 Dec 1998)
anti-HIV agents Agents used to treat aids and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with aids.
(12 Dec 1998)
antihypertensive agents Drugs used in the treatment of acute or chronic hypertension regardless of pharmacological mechanism. Among the antihypertensive agents are diuretics (especially diuretics, thiazide), adrenergic beta-antagonists, adrenergic alpha-antagonists, angiotensin-converting enzyme inhibitors, calcium channel blockers, ganglionic blockers, and vasodilator agents.
(12 Dec 1998)
anti-infective agents, local Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from disinfectants, which are used on inanimate objects.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á